vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $260.4M, roughly 1.2× Smith Douglas Homes Corp.). Smith Douglas Homes Corp. runs the higher net margin — 1.4% vs -18.2%, a 19.6% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs -9.4%). Smith Douglas Homes Corp. produced more free cash flow last quarter ($8.7M vs $-133.8M).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.

MDGL vs SDHC — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.2× larger
MDGL
$321.1M
$260.4M
SDHC
Growing faster (revenue YoY)
MDGL
MDGL
+220.2% gap
MDGL
210.8%
-9.4%
SDHC
Higher net margin
SDHC
SDHC
19.6% more per $
SDHC
1.4%
-18.2%
MDGL
More free cash flow
SDHC
SDHC
$142.6M more FCF
SDHC
$8.7M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MDGL
MDGL
SDHC
SDHC
Revenue
$321.1M
$260.4M
Net Profit
$-58.6M
$3.5M
Gross Margin
19.9%
Operating Margin
-18.6%
6.5%
Net Margin
-18.2%
1.4%
Revenue YoY
210.8%
-9.4%
Net Profit YoY
1.4%
-14.3%
EPS (diluted)
$-2.55
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
SDHC
SDHC
Q4 25
$321.1M
$260.4M
Q3 25
$287.3M
$262.0M
Q2 25
$212.8M
$223.9M
Q1 25
$137.3M
$224.7M
Q4 24
$103.3M
$287.5M
Q3 24
$62.2M
$277.8M
Q2 24
$220.9M
Q1 24
$0
$189.2M
Net Profit
MDGL
MDGL
SDHC
SDHC
Q4 25
$-58.6M
$3.5M
Q3 25
$-114.2M
$2.1M
Q2 25
$-42.3M
$2.4M
Q1 25
$-73.2M
$2.7M
Q4 24
$-59.4M
$4.1M
Q3 24
$-107.0M
$5.3M
Q2 24
$3.6M
Q1 24
$-147.5M
$3.0M
Gross Margin
MDGL
MDGL
SDHC
SDHC
Q4 25
19.9%
Q3 25
21.0%
Q2 25
23.2%
Q1 25
96.7%
23.8%
Q4 24
25.5%
Q3 24
26.5%
Q2 24
26.7%
Q1 24
26.1%
Operating Margin
MDGL
MDGL
SDHC
SDHC
Q4 25
-18.6%
6.5%
Q3 25
-39.7%
6.6%
Q2 25
-22.2%
7.7%
Q1 25
-57.8%
8.7%
Q4 24
-64.8%
10.4%
Q3 24
-187.1%
14.2%
Q2 24
11.7%
Q1 24
11.3%
Net Margin
MDGL
MDGL
SDHC
SDHC
Q4 25
-18.2%
1.4%
Q3 25
-39.8%
0.8%
Q2 25
-19.9%
1.1%
Q1 25
-53.4%
1.2%
Q4 24
-57.5%
1.4%
Q3 24
-172.0%
1.9%
Q2 24
1.7%
Q1 24
1.6%
EPS (diluted)
MDGL
MDGL
SDHC
SDHC
Q4 25
$-2.55
$0.39
Q3 25
$-5.08
$0.24
Q2 25
$-1.90
$0.26
Q1 25
$-3.32
$0.30
Q4 24
$-2.50
$0.50
Q3 24
$-4.92
$0.58
Q2 24
$0.40
Q1 24
$-7.38
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
SDHC
SDHC
Cash + ST InvestmentsLiquidity on hand
$198.7M
$12.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$602.7M
$86.7M
Total Assets
$1.3B
$557.6M
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
SDHC
SDHC
Q4 25
$198.7M
$12.7M
Q3 25
$295.7M
$14.8M
Q2 25
$186.2M
$16.8M
Q1 25
$183.6M
$12.7M
Q4 24
$100.0M
$22.4M
Q3 24
$232.7M
$23.7M
Q2 24
$17.3M
Q1 24
$622.5M
$32.8M
Total Debt
MDGL
MDGL
SDHC
SDHC
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
MDGL
MDGL
SDHC
SDHC
Q4 25
$602.7M
$86.7M
Q3 25
$625.7M
$82.2M
Q2 25
$696.0M
$80.0M
Q1 25
$710.6M
$76.9M
Q4 24
$754.4M
$73.6M
Q3 24
$777.2M
$68.4M
Q2 24
$62.1M
Q1 24
$850.8M
$59.7M
Total Assets
MDGL
MDGL
SDHC
SDHC
Q4 25
$1.3B
$557.6M
Q3 25
$1.4B
$571.6M
Q2 25
$1.0B
$570.2M
Q1 25
$996.6M
$513.9M
Q4 24
$1.0B
$475.9M
Q3 24
$1.1B
$460.1M
Q2 24
$429.3M
Q1 24
$1.1B
$401.3M
Debt / Equity
MDGL
MDGL
SDHC
SDHC
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
SDHC
SDHC
Operating Cash FlowLast quarter
$-133.5M
$9.8M
Free Cash FlowOCF − Capex
$-133.8M
$8.7M
FCF MarginFCF / Revenue
-41.7%
3.4%
Capex IntensityCapex / Revenue
0.1%
0.4%
Cash ConversionOCF / Net Profit
2.77×
TTM Free Cash FlowTrailing 4 quarters
$-36.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
SDHC
SDHC
Q4 25
$-133.5M
$9.8M
Q3 25
$79.8M
$22.8M
Q2 25
$-47.1M
$-28.9M
Q1 25
$-88.9M
$-34.9M
Q4 24
$-104.5M
$5.5M
Q3 24
$-67.0M
$22.9M
Q2 24
$39.0K
Q1 24
$-149.2M
$-9.3M
Free Cash Flow
MDGL
MDGL
SDHC
SDHC
Q4 25
$-133.8M
$8.7M
Q3 25
$79.0M
$21.4M
Q2 25
$-31.1M
Q1 25
$-35.9M
Q4 24
$-104.7M
$4.8M
Q3 24
$-67.8M
$22.3M
Q2 24
$-2.1M
Q1 24
$-149.5M
$-9.7M
FCF Margin
MDGL
MDGL
SDHC
SDHC
Q4 25
-41.7%
3.4%
Q3 25
27.5%
8.2%
Q2 25
-13.9%
Q1 25
-16.0%
Q4 24
-101.3%
1.7%
Q3 24
-109.0%
8.0%
Q2 24
-1.0%
Q1 24
-5.1%
Capex Intensity
MDGL
MDGL
SDHC
SDHC
Q4 25
0.1%
0.4%
Q3 25
0.3%
0.5%
Q2 25
0.0%
0.9%
Q1 25
0.0%
0.5%
Q4 24
0.2%
0.2%
Q3 24
1.3%
0.2%
Q2 24
1.0%
Q1 24
0.2%
Cash Conversion
MDGL
MDGL
SDHC
SDHC
Q4 25
2.77×
Q3 25
10.70×
Q2 25
-12.24×
Q1 25
-13.01×
Q4 24
1.33×
Q3 24
4.28×
Q2 24
0.01×
Q1 24
-3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

SDHC
SDHC

Southeast$164.7M63%
Central$95.8M37%

Related Comparisons